Drug intelligence / Profile preview

TPX-109

Development stage: Preclinical
Lead developer: Tego Science
Modality: Recombinant Proteins and Enzymes

Overview

TPX-109 is a recombinant chemokine biologic currently in preclinical development by Tego Science for the treatment of cartilage defects. As a signaling protein, TPX-109 is designed to modulate cellular responses to promote the repair and regeneration of damaged articular cartilage. This candidate represents a strategic expansion for Tego Science, moving beyond their core expertise in cell therapies (such as Kaloderm and Holoderm) into the development of protein-based regenerative medicines.

Beyond the preview

Go deeper on TPX-109.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TPX-109.

Explore the full profile